Ezetimibe
From Pharmacopedia
More actions
Ezetimibe
Zetia
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hyperlipidemia (alone or with a statin)0, Statin intolerance0, Familial hypercholesterolemia (combination)0, Post-ACS secondary prevention (with statin, per IMPROVE-IT)0
Pharmacy
Starting dose
10 mg PO once daily, with or without food
Preparations
10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist)
US FDA Max
10 mg/d
Pharmacology
Routes
Oral
Onset
LDL lowering within 2 weeks
Duration
24 hours
Half-life
~22 hours (parent + active glucuronide)[1]
Bioavailability
Variable (oral; rapidly conjugated to active glucuronide; food does not affect)[1]
Pregnancy
Limited data; generally avoided particularly in combination with statin.[citation needed]
Legal status
Rx-only in US
Purported mechanism
Ezetimibe binds the Niemann-Pick C1-like 1 (NPC1L1) transporter on the apical brush border of small-intestinal enterocytes, blocking the absorption of cholesterol (both dietary and biliary) without inhibiting absorption of triglycerides, fatty acids, bile acids, or fat-soluble vitamins.0 Reduced enterohepatic cholesterol delivery raises LDL receptor expression and lowers circulating LDL ~15-20% on top of statin. The IMPROVE-IT trial (2015) established that ezetimibe added to simvastatin improves post-ACS cardiovascular outcomes, validating the "lower LDL = better" hypothesis with a non-statin agent[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Zetia (ezetimibe), Merck/Schering, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021445s039lbl.pdf